Forbion
News
-
2013
Date Description 05.16.2013 
CircuLite® Receives Approval to Begin CE Mark Trial for SYNERGY® IC Circulatory Support System CircuLite®, Inc. today announced that it has received approval from the Federal Agency for Medicines and Health Products in Belgium to commence the CE Mark trial of the SYNERGY® IC Circulatory Support System, the first mechanical support system that does not require major surgery. The SYNERGY IC System is based on the surgical SYNERGY® Circulatory Support System – the world’s smallest commercially available circulatory support pump - which is designed to treat ambulatory chronic heart failure patients (INTERMACS ≥4).
05.13.2013 
Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prost... Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcom prostate biopsy. James McKiernan, M.D., professor of urology and the director of urologic oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York City presents the da today at 8 a.m. PDT.
05.08.2013 
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Respo... Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company’s improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response.
05.07.2013 
bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenk... bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Wendy Dixon, Ph.D., and David Schenkein, M.D., have joined the company’s board of directors.
04.29.2013 
Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors.
04.24.2013 
arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development.
04.23.2013 
Curetis raises EUR 12.5 million in Series B round Curetis AG today announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners, which has taken a EUR 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM will join Curetis’ supervisory board.04.19.2013 
Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therap... Pieris AG has achieved the second milestone for the first of two programs in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin.
04.18.2013 
Forbion Capital Partners co-leads €15 Million Series A Financing for Allecra Therapeutics Forbion Capital Partners, the Dutch life sciences venture capital firm, today announced that it has co-led the €15 million Series A financing round for Allecra Therapeutics GmbH, together with Edmond de Rothschild Investment Partners. EMBL Ventures was also part of the syndicate.
04.17.2013 
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted ... Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to discover and develop novel medicines using Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform.
-
2013
Date Description 04.16.2013 
Exosome Diagnostics Presents Data at the International Society for Extracellular Vesicles 2013 Annua... Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and microvesicle research.
04.10.2013 
Pieris and Sanofi Broaden Existing Collaboration Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin program. Under the existing framework of the 2010 agreement, the new program will entitle Pieris to an upfront payment from Sanofi and committed research funding as well as payments for the achievement of research, preclinical, regulatory and commercial milestones. Specific financial terms were not disclosed.
04.09.2013 
Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Tri... Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C. The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by Johan Skog, Ph.D., the newly appointed chief scientific officer of Exosome Diagnostics.
03.25.2013 
arGEN-X announces preclinical development of ARGX-112 for dermatology arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.
03.21.2013 
bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncolo... bluebird bio, a privately-held biotechnology company focused on gene therapy, today announced the formation of a broad, global strategic collaboration with Celgene Corporation to discover, develop and commercialize novel disease-altering gene therapies in oncology. The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.
03.14.2013 
Argos Therapeutics Welcomes Jean Lamarre to Board of Directors Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the appointment of Jean Lamarre, president of Lamarre Consultants, to its Board of Directors.
03.06.2013 
Curetis AG Strengthens Commercial Team and Expands Distribution Network Curetis AG today announced
The appointment of Helmut Hilbert as Head of Business Development and
the expansion of its distribution network into Belgium and Luxembourg by
closing a distribution agreement with ELITech BNL (former Lucron
Bioproducts), an ELITech Group company.
03.05.2013 
CircuLite® Receives Conditional IDE Approval for SYNERGY® Circulatory Support System feasibility Tri... CircuLite®, Inc. today announced that it has received conditional approval from the United States Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) for its lead product, the SYNERGY® Circulatory Support System, a minimally-invasive device designed to reverse the symptoms of heart failure in ambulatory chronic heart failure patients.
02.28.2013 
Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001 Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that is has raised a total of €14.2m ($18.6m ) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001(previously TA-8995) and to develop additional earlier-stage dyslipidemia assets.
02.21.2013 
uniQure Named to MIT Technology Review’s 2013 50 Disruptive Companies List Recognizing World’s Most ... uniQure has been identified in the field of biomedicine as one of 2013’s 50 Disruptive Companies, MIT Technology Review’s annual list of theworld’s most innovative technology companies. The honorees are nominated by MIT Technology Review’s editors, who look for companies that have demonstrated original and valuable technology over the last year,are bringing that technology to market at significant scale, and are clearly influencing their competitors.Spanning energy and materials, Internet and digital media, computing and communications, biomedicine, and transportation, the 50 companies on the list represent the disruptive innovations most likely to change our lives.
-
2013
Date Description 02.15.2013 
Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metasta... Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced updated results from its Phase 2 study of AGS-003, its most advanced product candidate for the treatment of metastatic renal cell carcinoma (mRCC). The results, presented in a poster session at the 2013 ASCO Genitourinary Cancers Symposium in Orlando, continue to show prolonged survival in patients with unfavorable risk mRCC, with one-third of patients still alive after nearly four years or longer.
01.29.2013 
Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced today its Chief Operating Officer and Vice President of Manufacturing, Dr. Frederick Miesowicz, will present during two focus sessions at Phacilitate's 9th Annual Cell and Gene Therapy Forum on January 28 and 29 in Washington, D.C.
01.22.2013 
uniQure Appoints Philip Astley-Sparke President US uniQure B.V., the leader in the field of human gene therapy, today announced the appointment of Philip Astley-Sparke, former President and CEO of BioVex, as President US to provide strategic leadership and help build uniQure’s clinical, regulatory, and commercial infrastructure in the US.
01.22.2013 
Dezima Pharma in-licenses CETP Inhibitor Program Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the inlicensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.
01.15.2013 
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate. AGS-003 is an investigational, fully personalized, dendritic-cell based immunotherapy. The ADAPT study is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend overall survival versus standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma (mRCC).
01.08.2013 
arGEN-X Expands its Therapeutic Anitbody Alliance with Shire arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody products, is broadening its therapeutic antibody collaboration with Shire. Initiated in March 2012, the existing alliance is focused on arGEN-X using its SIMPLE Antibody™ discovery platform to create novel human antibody therapeutics addressing diverse rare and unmet diseases being pursued by Shire.
01.08.2013 
arGEN-X Initiaties Phase Ib Study of ARGX-110 in Cancer arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery.
-
2012
Date Description 12.17.2012 
Promedior Opens New Office and Laboratories in Lexington, Mass. Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Massachusetts.
12.11.2012 
uniQure licenses RNA interference technology uniQure B.V., a leader in the field of human gene therapy, today announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. (ASX: BLT) giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington’s disease. In return, uniQure granted Benitec non-exclusive access to the Company’s AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.
12.11.2012 
uniQure initiates Phase I in acute intermittent porphyria uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first
patient. The study is conducted under the aegis of the AIPGENE consortium, a pan-European collaboration funded in part by the European Commission’s Seventh Framework Program with the aim to develop a gene therapy for the treatment of AIP, a rare and devastating disease caused by mutations in the porphobilinogen deaminase gene(PBGD). AIP can be life-threatening and the long-term effects include irreversible nerve damage, liver cancer and kidney failure. uniQure was granted orphan drug designation for the treatment of AIP in 2009 from the European Medicines Agency.12.11.2012 
uniQure Appoints Hans Christian Rohde Chief Commercial Officer uniQure B.V., a leader in the field of human gene therapy, today announced the appointment of Hans Christian Rohde as Chief Commercial Officer.
12.10.2012 
arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform arGEN-X, a biopharmaceutical company focused on the discovery and development of highly differentiated human monoclonal antibody therapeutics has received its first Notice of Allowance from the United States Patent and Trademark Office (USPTO) in connection with a portfolio of patent filings related to its SIMPLE Antibody™ discovery platform.
12.04.2012 
Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of Unyvero Cartridge Plastic... Curetis AG today announced a strategic supply chain partnership with German family business Horst Scholz GmbH + Co. KG for the production of high-quality plastics parts for its Unyvero Cartridge. Under the agreement, Curetis will invest more than € 2 million in multi-cavity tools for all Unyvero™ Cartridge plastics parts. Curetis has already ordered several multi-cavity tools from Scholz. The first tools will be delivered in early 2013.
Scholz has been chosen by Curetis due to its unrivalled experience and expertise in medical device-grade injection molding, its state-of-the-art facilities and equipment as well as its cleanroom manufacturing infrastructure.
11.29.2012 
Pieris Presents Data and Reveals Targets for Anticalin Bispecific In a presentation yesterday at the 8th Annual European Antibody Congress in Geneva, Switzerland, Pieris AG presented for the first time data for its PRS-190 bispecific Anticalin program targeting the Th17 pathway. The data revealed the generation of a highly specific and potent bispecific antagonist targeting IL-17 and IL-23, two key members of the Th17 family of cytokines, involved in autoimmunity and hyperinflammation. The single-gene multispecific drug candidate, whose individual building blocks could surpass existing available therapies against their respective target, creates several benefits ranging from efficacy, convenience, accelerated development timelines, ease of manufacturing and cost.
11.19.2012 
Study shows innovative ERT‐based solution has the potential to address unmet clinical needs across a... Oxyrane, today announced the publication in Nature Biotechnology, results of its landmark study in novel enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs). Oxyrane, in collaboration with VIB researchers from Ghent University and Vrije Universiteit Brussels, have developed a new technology that enables a more efficient approach to ERT production for LSD treatments, as well as the potential to significantly improve future treatments for debilitating and often life‐threatening LSDs such as Pompe disease, Fabry disease and Hunter’s syndrome.
11.19.2012 
Forbion Announces Appointment of Two Leading Experts in Oncology and Metabolic Disease as Scientific... Forbion Capital Partners today announced the appointment of Dr Kapil Dhingra, formerly global leader in oncology at Roche, and Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the University of Amsterdam, as Scientific Advsors. They will be advising on oncology and metabolic disease investment opportunies respectively.
11.15.2012 
Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of its RNA-Based Im... Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings that confirms the Company’s current methods of analyzing RNA are robust and optimal for the assessment of RNA quality needed to develop the Company’s novel immunotherapies. The study, which was published in the November issue of the Journal of Pharmaceutical and Biomedical Analysis, the journal of the American Association of Pharmaceutical Scientists, compared traditional slab electrophoresis currently in use at Argos to a newer microfluidics-based platform for performing various RNA analyses.
-
2012
Date Description 11.13.2012 
Insmed Announces CLEAR-108 Phase 3 Clinical Study Has Completed Target Enrollment Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CLinical Evaluation of ARIKACE (CLEAR-108) phase 3 European and Canadian registrational study of ARIKACE® (liposomal amikacin for inhalation) for Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections has now enrolled over 300 patients.
CLEAR-108 is a randomized, phase 3 trial comparing ARIKACE 560 mg, delivered once daily via an optimized, investigational eFlow® Nebulizer System (PARI Pharma GmbH), to TOBI® (1) (tobramycin solution for inhalation), which is a commercially available inhaled antibiotic that is delivered twice daily. The study is being conducted in over 300 patients in Europe and Canada.
11.07.2012 
Insmed Appoints Andrew Drechsler as Chief Financial Officer Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler to the position of Chief Financial Officer. Mr. Drechsler will assume the role of Principal Financial and Accounting Officer as of November 8, 2012.
11.02.2012 
Southeast BIO Recognizes Argos Therapeutics with the "2012 Southeast BIO Deal of the Year Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its ArcelisTM technology platform, was presented with the "2012 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO) 14th Annual Investor Forum on November 1, 2012 in Palm Beach, FL. B. Jefferson (Jeff) Clark, a member of Argos Therapeutics’ Board of Directors, accepted the award on the behalf of company.
11.02.2012 
Forbion Portfolio Company uniQure receives Approval for Glybera® First Gene Therapy by European Comm... Forbion Capital Partners is pleased to announce that its investee company, uniQure received approval today from the European Commission (EC) for the gene therapy Glybera® (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis. Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world.
10.26.2012 
Exosome Diagnostics Selects Promega Corp. for cGMP Clinical Sample Concentrator Kit Exosome Diagnostics today announced it has reached an agreement with Promega Corporation to be the exclusive supplier of its Urine Clinical Sample Concentrator Kit. Promega will manufacture the Clinical Sample Concentrator Kit under current good manufacturing practices (cGMP) in their Madison, Wisconsin manufacturing facility. The kit incorporates Exosome's proprietary method for concentration of urinary exosomes, a standardized approach for providing clinical laboratories access to high quality preparations suitable for molecular diagnostics. The kit will be used to process urine samples for clinical trials in genitourinary disorders, including prostate cancer.
10.25.2012 
ARGEN-X appoints Dr. David L. Lacey to its Supervisory Board arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.
Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the human anti-RANKL mAb denosumab, which was approved in 2010 by the U.S. Food and Drug Administration (FDA) under the trade name Prolia to treat osteoporosis in postmenopausal women and as Xgeva for the prevention of skeletal-related events in metastatic bone tumors. He was most recently responsible for leading more than 1,200 scientists in Amgen's discovery research unit across a portfolio of discovery and preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience.
10.15.2012 
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Elizabeth G. Trehu, M.D., as Chief Medical Officer (CMO). As CMO, Dr. Trehu will oversee all clinical development and regulatory activities for the company, as Promedior rapidly advances its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal diseases. Dr. Trehu is a seasoned biopharmaceutical executive with experience moving early stage R&D programs successfully through clinical development and product commercialization. She will report directly to Promedior’s CEO Suzanne Bruhn, Ph.D., and will serve as a member of the company’s executive management team.
10.15.2012 
Promedior Expands Series D Round of Financing Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that it has completed a $24.5 million Series D financing round, adding $3 million in a second closing of this financing round from new investor, Shire Strategic Investment Group. The first close of the financing was led by another new investor, Fibrotec Ventures, LLC, and the round includes participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.
10.10.2012 
Eric Rose, M.D., named Chairman of the CircuLite Board of Directors CircuLite today announced the appointment of Eric Rose, M.D., as Chairman of its Board of Directors. Dr. Rose is a recognized leader in academic medicine and surgery and an entrepreneur. His interests range from device development to drug discovery, biodefense, clinical evaluative research and health policy. He is Executive Vice President of Life Sciences at MacAndrews & Forbes and has been a Director of CircuLite since November 2011.
10.09.2012 
Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therap... Pieris AG announced today the achievement of the first financial milestone in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568). The milestone recognizes the on-schedule selection, optimization and characterization of several Anticalin drug candidates, developed using Pieris’ proprietary next-generation scaffold technology, against a Daiichi Sankyo target. The financial details of the milestone payment have not been disclosed.
-
2012
Date Description 10.09.2012 
Curetis Completes Enrollment for its EU Trial Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal.
10.04.2012 
RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a... Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the achievement of certain clinical, regulatory and commercialization milestones and royalties based on worldwide net sales of therapeutic products.
09.27.2012 
Amakem Initiates Phase 2a Proof of Concept Study with the Rho Kinase (ROCK) Inhibitor AMA0076 in Pat... Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension. The start of the study follows Amakem’s receipt of Investigational New Drug Application (IND) approval from the United States Food and Drug Administration (FDA). AMA0076 is a highly potent ROCK inhibitor and is based on Amakem’s ‘Localized Drug Action’ platform, which generates novel kinase inhibitors that minimize the risk of systemic as well as local side effects such as hyperemia.
09.26.2012 
Teijin Pharma and Pulmagen Therapeutics Sign Exclusive Agreement Tokyo-based Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Pulmagen Therapeutics (Asthma) Limited, a UK-based drug development company, announce today an exclusive licensing agreement granting Teijin Pharma the rights to develop, manufacture and market ADC3680, a bronchial asthma therapeutic discovered by Pulmagen Therapeutics, in Japan.
09.20.2012 
21st Century Health and Business highlighted novoGI novoGI Inc. today reported that 21st Century Health and Business, the health and medical related business television program, that showcases insights from cutting edge corporations around the world and innovative business strategies, highlighted novoGI and its compression anastomosis solution and its revolutionary approach to GI disease management.
09.19.2012 
Curetis AG to Present Its UnyveroTM Solution at DGHM Conference Curetis AG today announced the presentation of its UnyveroTM Solution for the rapid molecular diagnosis of infectious diseases and the UnyveroTM P50 Pneumonia Cartridge during the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM) in Hamburg.
09.11.2012 
Insmed Appoints Will Lewis as President and Chief Executive Officer Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced the appointment of Will Lewis as President and Chief Executive Officer, effective immediately. Mr. Lewis has also been appointed to the Company's Board of Directors. He succeeds Tim Whitten, who has resigned as President and Chief Executive Officer and as a member of the Company's Board of Directors. In addition, Donald J. Hayden, Jr., who was appointed Executive Chairman in May 2012, will return to his role as Chairman, effective immediately.
09.10.2012 
Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO of BioVex, has joined the investment team as a venture partner based in Boston, USA. He will work with selected Forbion’s portfolio companies as a board member and/or advisor to help management to execute on their business plans.
09.05.2012 
Forbion Portfolio Company Circulite® Receives CE Marking Approval For SYNERGY® Circulatory Support S... Forbion portfolio company CircuLite®, Inc. today announced that it has received CE Marking approval for the SYNERGY® Circulatory Support System, a micro-pump designed to halt the progression of heart failure.
07.25.2012 
bluebird bio Secures $60 Million in Oversubscribed Financing Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple Clinical Programs in Severe Genetic Disorders, Including a Global ALD Phase 2/3 Study
-
2012
-
2012
-
2012
-
2012
-
2011
-
2011
-
2011
-
2011
-
2011
-
2011
-
2010
-
2010
-
2010
-
2010
-
2010
Date Description 02.03.2010 
Galapagos acquires Argenta Discovery's service operations 01.25.2010 
EMA starts formal review of Glybera? dossier 01.20.2010 
AMT submits its lead product Glybera? Application for Marketing Authorisation Application to EMA 01.04.2010 
Pieris appoints a new CEO -
2009
-
2009
-
2009
-
2009
-
2008
-
2008
-
2008
-
2007
Date Description 12.20.2007 
Forbion Capital Partners expands investment team with Sr. Analyst and Venture Partner 12.18.2007 
Santaris Pharma raises €20 million of new equity 12.13.2007 
Forbion Capital Partners leads EUR30M Series B Financing in Fovea Pharmaceuticals S.A. 12.11.2007 
BioVex closes second round of series E financing - 15 November 2007 12.11.2007 
BioVex appoints Genzyme executive Jan van Heek as chairman of the Board of Directors - 25 October 20... 12.10.2007 
Mitralign Announces the Closing of a $24M Series C Financing 12.03.2007 
Cytheris Releases Promising Clinical Data on it's Interleukin-7 Immune Enhancer at the 2007 CROI Mee... 11.27.2007 
Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong... 09.24.2007 
FlowMedica Inc. Launches the Benephit® XT Infusion System. The Next-Generation System for Target... 08.30.2007 
FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry - 2... -
2007
-
2007
-
2007
-
2006
Date Description 12.13.2006 
Analysis by AlgoNomics reveals that Anticalins® intrinsically have an immunogenicity level comparabl... 12.12.2006 
Amsterdam Molecular Therapeutics BV (AMT) Acquires License to AAV Patents from Targeted Genetics Cor... Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South
Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an
offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South
Africa, Australia, Japan or any other jurisdiction.Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South
Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an
offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South
Africa, Australia, Japan or any other jurisdiction.11.17.2006 
First closing of BioGeneration Ventures Fund 11.02.2006 
Pathway Medical closes $25 million Series B funding raising 10.25.2006 
Pieris confirms in vivo activity of potent VEGF-specific Anticalin 10.25.2006 
Cytheris closes EUR 24.3M (USD 30.7M) Series B financing Funds to progress Phase II clinical studies... 10.24.2006 
Alantos pharmaceuticals and servier form collaboration 10.12.2006 
Claus Braestrup, CEO of Lundbeck, appointed to Santaris Pharma Board Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas ac libero vel erat tincidunt euismod. Etiam faucibus eleifend arcu, non consequat justo lobortis et. Sed egestas, enim et tempus tristique, augue lectus mattis mi, eu condimentum nibh purus quis felis. In pharetra leo aliquam massa porttitor nec blandit felis bibendum. Proin egestas sapien quis purus elementum ut egestas purus molestie. Etiam fermentum, dui nec vestibulum posuere, massa velit tincidunt nisi, nec ultricies erat libero quis enim. Maecenas rutrum, nibh in blandit volutpat, risus massa ullamcorper turpis, non semper metus diam sed augue. Aenean lorem lacus, vestibulum a faucibus a, elementum sit amet sem. Aliquam dolor leo, vehicula quis tincidunt ut, posuere sed neque. Maecenas nisl diam, hendrerit non venenatis vel, malesuada vitae turpis. Sed scelerisque pharetra consectetur. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Fusce a massa lorem, ut luctus lacus.
Morbi a dolor erat, sit amet porta neque. Praesent consequat, lacus quis vulputate commodo, eros sapien fermentum massa, et luctus libero ante a quam. Nulla pulvinar dapibus tempus. Aliquam sed nisi dolor, at vulputate risus. In est arcu, suscipit non eleifend sed, venenatis eu est. Nullam justo nisi, bibendum eget pulvinar sed, ultrices scelerisque metus. Vivamus fermentum leo et risus aliquet nec pulvinar lorem convallis. Quisque rutrum, mi non accumsan mollis, lectus ante euismod elit, in pulvinar lectus orci eu sapien. Etiam auctor eleifend felis, id mattis tortor consectetur ac. Curabitur nec est velit, eget vehicula quam. Vestibulum eleifend condimentum congue. Aliquam dictum purus vel turpis porta pretium. In consequat, sapien et feugiat ultricies, mi augue egestas massa, tempor ullamcorper justo est non massa. Sed auctor enim at tellus viverra vitae consequat felis imperdiet.
Nullam vitae vehicula magna. Etiam elementum diam id dolor tincidunt ac sagittis neque consectetur. Nullam in feugiat lectus. Aliquam sollicitudin tempus tristique. Nullam bibendum mauris vel magna fermentum adipiscing. Duis vestibulum turpis vel magna accumsan tempor. Aenean lorem ligula, ornare vel vehicula quis, placerat et nisi. Pellentesque urna nunc, aliquam ac adipiscing eu, mollis a tortor. Praesent pharetra libero pulvinar arcu luctus tristique. Pellentesque a pharetra est. Nullam bibendum, elit vel congue facilisis, lorem risus aliquam justo, non aliquet magna odio quis dui. Nullam convallis porta libero eu bibendum. Nulla eu tortor nec turpis mollis consectetur. Vivamus eget augue at lacus dictum consequat. Praesent in velit arcu, pellentesque tincidunt sem. Pellentesque in consequat lacus.
